Biotech success in Australia without the long wait and the big budgets

Stuart Roberts

Pitt Street Research and NDF Research

Last week we at NDF Research told you about the The Coming Boom in Life Sciences in Australia. A great example of the potential upside is a virtually unknown listed biotech company called Dimerix (ASX: DXB). I like this company because of what they can potentially achieve without the long wait or the big budgets traditionally associated with biotechnology. Dimerix is now in Phase II - the mid-stage of clinical trials - with DMX-200. This product is a combination of two existing and approved drugs, irbesartan and propagermanium. Following recent guidance for the FDA, Dimerix now plans to take DMX-200 into Phase III in a rare kidney disorder called FSGS. Using existing drugs and going after a rare disease for the first approval were both smart moves that markedly cut the potential cost and time required to get to market, and there's still a US$10bn market waiting for the larger market indications in kidney disease that will follow. Dimerix shows how we're getting really good at building biotech companies here in Australia. Check out my Dimerix report at (VIEW LINK)


Stuart Roberts
Founder and Senior Analyst
Pitt Street Research and NDF Research

I am an equity research professional who worked in stockbroking from 2001 to 2015. After 15 months doing investor relations I returned to equity research with the founding of NDF Research. With Marc Kennis I founded Pitt Street Research in July 2018.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.